Notably, KIF2A and KIF20A not only have potential as useful biomarkers for predicting prognosis, but also can serve as novel and potential therapeutic targets in various malignant tumors through different mechanisms.[21] In 2013, a Japanese scientific research team performed a single-center phase I/II clinical trial of immunotherapy and developed a pancreatic cancer vaccine, KIF20A-66, composed of human leukocyte antigen human leukocyte antigen-A24-restricted epitope peptide derived from KIF20A.[52] This vaccine significantly prolonged the OS of patients. Here, KIF2A is linked to familial pancreatic carcinoma.